(Q46648562)

English

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

scientific article published in August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Philip W. Kantoff

10

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Mary-Ellen Taplin

1

object named as

Mary-Ellen Taplin

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

author name string

Daniel J George

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Susan Halabi

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Ben Sanford

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Philip G Febbo

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Kristen T Hennessy

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Christos G Mihos

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Nicholas J Vogelzang

8

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Eric J Small

9

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

66

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

386-391

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

The Ingredients for Prostate Cancer Nomograms: The Addition of Biomarkers Sets the Table for Future Recipes

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Neuroendocrine differentiation in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

The Prognostic Value of Neuroendocrine Differentiation in Adenocarcinoma of the Prostate in Relation to Progression of Disease After Endocrine Therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Circulating neuroendocrine markers in patients with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Gene expression correlates of clinical prostate cancer behavior

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Elevated Plasma Chromogranin-A Concentrations in Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.040

7 January 2021

Identifiers

10.1016/J.UROLOGY.2005.03.040

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16098367

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46648562&oldid=2124263514"